A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen

By Antonietta Impagliazzo, F. Milder, H. Kuipers, M. Wagner, Xueyong Zhu, Ryan M. B. Hoffman, Ruud van Meersbergen, Jeroen Huizingh, P. Wanningen, Johan W. A. Verspuij and 20 more. 2015

565 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Immunology

Citations in the corpus

Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses (2020, background): “Immunization: 2-based HA stem immunogens convincingly elicit protective antibody responses that overcome the group boundary in animal models [32] [33] [34] 40 .”
Next-Generation Influenza Vaccines. (2020, background): “2020), headless HA stem trimers delivered as soluble proteins (Impagliazzo et al. 2015), or displayed on nanoparticles (Yassine et al.”
New Vaccine Design and Delivery Technologies (2019, background): “Common strategies include designing disulfide bonds to immobilize linked domains [28] [29] [30] [31] [32] , improved hydrophobic packing to stabilize a particular conformational state [22, 33] , proline mutations to constrain conformational flexibility, and proline/glycine mutations to discourage he”
Quantifying B cells capable of producing broadly neutralizing antibodies against influenza serves as a metric to guide the development of a universal influenza vaccine (2016, unknown): “…immunization with a divergent influenza (Figures 6A and 7F), likely by enhancing immune focus to the HA stem (Figures 7G and 7H), an approach utilized by ‘‘stem-only’’ or ‘‘headless’’ immunogens (Impagliazzo et al., 2015; Yassine et al., 2015) and by chimeric HA immunogens (Krammer et al., 2015).”
Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem (2019, unknown): “While targeting the stem has energized efforts to develop universal influenza vaccines (6, 7), stem-specific antibodies in humans are generally found at low serological concentrations (8), with only limited increases after seasonal immunization or infection (3, 9, 10).”
A Hemagglutinin Stem Vaccine Designed Rationally by AlphaFold2 Confers Broad Protection against Influenza B Infection (2022, methodology): “Additionally, we also introduced mutations to further improve the structural stability by referring the design of mini-HA [21].”
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen (2017, background): “Notably, the identification of stem-directed antibodies against influenza HA (35) represented a paradigm shift in the approach to develop a universal influenza vaccine, with recent studies demonstrating substantial promise (33, 34).”
Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages (2018, unknown): “We and others have recently developed influenza A group 1 HA stem trimer 80 antigens (17, 18).”
Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers (2020, methodology): “ELISAs were also used to evaluate recognition of CA09-miniHA, a stabilized stem-only construct derived from CA09 HA [11] to investigate whether there was preferred recognition of stem epitopes by the animals immunized with mosaic NPs.”